Coronavirus Notebook: EU Joins COVAX, Sanofi/GSK Vaccine Moves To Phase I/II
Convalescent plasma has taken another battering as a potential treatment for coronavirus patients, after a UK drug safety body agreed with a US expert panel that there was not yet enough evidence to recommend its use in COVID-19 patients.
You may also be interested in...
Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.
The UK government is proposing to take the "very unusual step" of making COVID-19 vaccines available before they are licensed. The international COVAX initiative is now supporting nine vaccines, and the EU and AstraZeneca have firmed up a vaccine purchase agreement.